Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Social Cognition

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Social Cognition. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2006-004435-30 Sponsor Protocol Number: SC06-02 Start Date*: 2006-10-31
    Sponsor Name:FONDAZIONE SANTA LUCIA
    Full Title: Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients.
    Medical condition: Patients with cognitive and behavioural disorders following severe TBI and other severe acquired brain injury Glasgow Coma Scale GCS lower or equal 8
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057668 Cognitive disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003331-10 Sponsor Protocol Number: HC03 Start Date*: 2017-10-16
    Sponsor Name:Leiden University
    Full Title: Acute effects of 40 mg cortisol on emotion and cognition.
    Medical condition: None.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000258-64 Sponsor Protocol Number: D1449L00004 Start Date*: 2005-04-08
    Sponsor Name:AstraZeneca AB
    Full Title: SCORE An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Co...
    Medical condition: Schizophrenia is a chronic psychiatric disorder that often begins during adolescence or early adulthood. A major problem for patients with schizophrenia is a cognitive deficit compared to a control...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004729-97 Sponsor Protocol Number: 2018-PWL Start Date*: 2019-08-16
    Sponsor Name:Dutch Growth Research Foundation
    Full Title: Randomized, controlled growth hormone study in children and adolescents with a Prader-Willi-like phenotype, followed by a two year open-label growth hormone study - effects on body composition, gro...
    Medical condition: Prader-Willi-like phenotype
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10018747 Growth hormone LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004172-17 Sponsor Protocol Number: ETES Start Date*: 2021-04-26
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Electroconvulsive therapy vs. esketamine nasal spray in treatment-resistant depression: a longitudinal, randomized efficacy comparison pilot study
    Medical condition: treatment resistant depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000504-37 Sponsor Protocol Number: 2020PI215 Start Date*: 2021-04-01
    Sponsor Name:CHRU DE NANCY
    Full Title: Characterization by PET-CT with 18F-FDG of brain lesions in young subjects with sequential psycho-cognitive disorders following severe COVID19
    Medical condition: young subjects with sequential psycho-cognitive disorders in the aftermath of severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004863 10084547 Exposure to COVID-19 LLT
    21.1 10029205 - Nervous system disorders 10057668 Cognitive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001975-12 Sponsor Protocol Number: V00191 PO 202 Start Date*: 2007-07-18
    Sponsor Name:PIERRE FABRE MEDICAMENT - IDPF
    Full Title: Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel...
    Medical condition: Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) FI (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006130-16 Sponsor Protocol Number: EFFECTS2012 Start Date*: 2014-08-08
    Sponsor Name:Karolinska Institutet
    Full Title: ESTABLISHING THE EFFECT(S) AND SAFETY OF FLUOXETINE INITIATED IN THE ACUTE PHASE OF STROKE
    Medical condition: Cerebrovascular diseases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000143-12 Sponsor Protocol Number: ORBIS-DE-UNIBO001 Start Date*: 2019-07-25
    Sponsor Name:ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA
    Full Title: OXYTOCIN RESEARCH FOR BEHAVIORAL IMPAIRMENT SYMPTOMS IN DEMENTIA: Potential clinical efficacy of intranasal oxytocin in the treatment of frontotemporal dementia. A randomized, double-blind, placebo...
    Medical condition: Frontotemporal dementia (bvFTD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002708-26 Sponsor Protocol Number: CRC341 Start Date*: 2017-06-28
    Sponsor Name:University of Surrey
    Full Title: A randomised double blind placebo controlled pilot trial of oxytocin efficacy in treating detoxified opioid dependent individuals
    Medical condition: Opioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individua...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10057379 Addiction relapse LLT
    20.0 100000004873 10001126 Addiction any drug LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005138-21 Sponsor Protocol Number: TC-5619-23-CRD-003 Start Date*: 2012-04-03
    Sponsor Name:Targacept Inc.
    Full Title: A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in ou...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005239-15 Sponsor Protocol Number: MISO Start Date*: 2016-08-12
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?
    Medical condition: depressed patients and healthy control subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001422-25 Sponsor Protocol Number: ITA-BGT-12-10389 Start Date*: 2013-06-11
    Sponsor Name:Biogen Idec Italia S.r.l.
    Full Title: Single country study assessing cognition in Relapsing Remitting Multiple Sclerosis patients treated with BG00012
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003529-41 Sponsor Protocol Number: ABR58805 Start Date*: 2017-02-22
    Sponsor Name:University Medical Center Utrecht
    Full Title: CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia
    Medical condition: Schizophrenia patients
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005000-17 Sponsor Protocol Number: CAFQ056A2225 Start Date*: 2013-08-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Seroton...
    Medical condition: obsessive compulsive disorder (OCD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 100000004873 10002862 Anxiety disorders NEC (incl obsessive compulsive disorder) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004079-38 Sponsor Protocol Number: 01112012 Start Date*: 2013-01-14
    Sponsor Name:Central Institute of Mental Health, Department of Psychiatry and Psychotherapy
    Full Title: Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH). A single arm, prospective pilot study
    Medical condition: Major depressive episode
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004193-64 Sponsor Protocol Number: RVP-30-001 Start Date*: 2022-06-29
    Sponsor Name:Reviva Pharmaceuticals Holdings Inc.
    Full Title: Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia...
    Medical condition: Acute Exacerbation of Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001064 Acute schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000579-40 Sponsor Protocol Number: D1443L00002 Start Date*: 2007-10-10
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003466-33 Sponsor Protocol Number: 1103-011 Start Date*: 2013-05-17
    Sponsor Name:Mental Health Services North Holland North
    Full Title: Memantine Add-On Therapy to Clozapine
    Medical condition: Cognitive functioning, severity of psychopathology and treatment response (positive symptoms and negative symptoms of schizophrenia), depressive symptoms, social cognition, obsessive-compulsive sy...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004829-82 Sponsor Protocol Number: GHREDECIDE Start Date*: 2019-04-16
    Sponsor Name:Linköping University
    Full Title: Effects of the appetite-inducing hormone ghrelin on decision making in healthy volunteers
    Medical condition: NA, healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA